Bayer(BAYRY.US)

Last Updated 19:00:00 ET
longbridge loading

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

nasdaq·
DE
BAYN
0.00%
US
BAYRY
+0.64%
US
XLV
+0.89%
nasdaq·
DE
BAYN
0.00%
US
BAYRY
+0.64%
US
XLV
+0.89%

Barclays Remains a Buy on Bayer (0P6S)

Tip Ranks·
US
BAYRY
+0.64%
US
PBE
-0.24%
US
SBIO
-1.63%
Tip Ranks·
US
BAYRY
+0.64%
US
PBE
-0.24%
US
SBIO
-1.63%

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack | BAYRY Stock News

StockTitan·
US
BAYRY
+0.64%
US
PBE
-0.24%
US
IBB
-0.29%
StockTitan·
US
BAYRY
+0.64%
US
PBE
-0.24%
US
IBB
-0.29%

U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer | BAYRY Stock News

StockTitan·
US
BAYRY
+0.64%
US
VHT
+0.60%
US
IXJ
+0.69%
StockTitan·
US
BAYRY
+0.64%
US
VHT
+0.60%
US
IXJ
+0.69%
© 2026 Longbridge｜Disclaimer